

# GUIDE FOR HEALTHCARE PROFESSIONALS

## SOLIQUA® (INSULIN GLARGINE 100 UNITS/mL + LIXISENATIDE)—AVAILABLE IN 2 PRE-FILLED PENS CONTAINING DIFFERENT DOSAGE STRENGTHS.

This Guide for Healthcare Professionals is intended to raise the awareness of healthcare professionals to the differences between the two available Soliqua® pre-filled pens as well as their dosing and usage instructions, thereby facilitating their training of patients on the correct use of Soliqua®.

This document is supplied only as a guide. Please refer to the Singapore package insert before prescribing and dispensing either of the SOLIQUA® pens.

## A CHECKLIST FOR HEALTHCARE PROFESSIONALS

### EXPLAIN TO YOUR PATIENT

- ☐ You are prescribing a number of dose steps that corresponds to a set number of Units of insulin glargine 100 U/mL plus a corresponding amount of lixisenatide.
- ☐ For SOLIQUA®, one dose step always contains one Unit of insulin glargine, regardless of the SOLIQUA® pre-filled pen being used (the SOLIQUA® [10-40] pen or the SOLIQUA® [30-60] pen).
- ☐ The dose pointer shows the number of dose steps to be injected.
- ☐ If your patient has been transferred from a different pre-filled pen device, highlight the differences in design between the two devices (focus on color differentiation and warning statements on packaging/label).
- ☐ Explain what the patient should anticipate regarding dysglycaemia and potential adverse reactions. For a complete list of adverse events, please refer to the SOLIQUA® Singapore Package Insert.
- ☐ Tell patients to closely monitor their blood sugar levels when starting SOLIQUA®, which contains insulin glargine 100 U/mL and a non-insulin active substance (lixisenatide).
- ☐ Patients who are blind or have poor vision must be instructed to always get assistance from another person who has good vision and is trained in the SOLIQUA® pen device.
- ☐ Instruct your patients to always use a new needle before each use and to never use a syringe to remove the solution from the pen to avoid dosing errors and potential overdose.
- ☐ Recommend that your patients read the patient information leaflet carefully, as well as the instructions for use leaflet provided in the SOLIQUA® packaging.


## IMPORTANT INFORMATION ON DOSING

- SOLIQUA® is available in 2 pre-filled pens containing different strengths of lixisenatide and different dose ranges of insulin glargine, to treat patients with different insulin needs up to 60 units of insulin glargine:

### SOLIQUA® 10-40 PEN

(10 to 40 dose steps)

Containing insulin glargine 100 units/mL  
with lixisenatide 50 micrograms/mL




#### FIXED RATIO 2:1

- Insulin glargine (100 Units/mL): 10 – 40 Units/day
- Lixisenatide (50 mcg/mL): 5 – 20 mcg/day
- Each dose step contains 1 unit of insulin glargine and 0.5 mcg of lixisenatide

### SOLIQUA® 30-60 PEN

(30 to 60 dose steps)

Containing insulin glargine 100 units/mL  
with lixisenatide 33 micrograms/mL



#### FIXED RATIO 3:1

- Insulin glargine (100 Units/mL): 30 – 60 Units/day
- Lixisenatide (33 mcg/mL): 10 – 20 mcg/day
- Each dose step contains 1 unit of insulin glargine and 0.33 mcg of lixisenatide

# IMPORTANT INFORMATION ON DOSING

- Both SOLIQUA® SoloStar® pens simultaneously deliver insulin glargine 100 U/mL and the prandial glucagon-like peptide-1 receptor agonist (GLP-1 RA) lixisenatide in 2 different fixed-ratio solutions for a single, once-daily injection.
- Both pre-filled pens contain insulin glargine in a strength of 100 Units/mL.
- The dose of SOLIQUA® is expressed in ‘dose steps’, with each dose step corresponding to one unit of insulin glargine plus a fixed amount of lixisenatide.
- The SOLIQUA® (10-40) pen allows a once-daily injection of doses between 10 and 40 dose steps
  - Strength: insulin glargine 100 Units/mL and lixisenatide 50 mcg/mL;
  - Dose range: 10 to 40 Units of insulin glargine in combination with 5 to 20 mcg lixisenatide.
  - This pen is peach colored with an orange injection button.
- The SOLIQUA® (30-60) pen allows a once-daily injection of doses between 30 and 60 dose steps
  - Strength: insulin glargine 100 Units/mL and lixisenatide 33 mcg/mL;
  - Dose range: 30 to 60 Units insulin glargine in combination with 10 to 20 mcg lixisenatide.
  - This pen is olive colored with a brown injection button.
- Since the two pens contain different amounts of lixisenatide for each dose step, it is important that they are not used interchangeably as this would result in patients receiving too much or too little lixisenatide. This could lead to fluctuations in blood glucose control

## STARTING DOSE TABLE

- The dose must be individualised based on clinical response and is titrated based on the patient’s need for insulin.

		Previous Therapy		
		Insulin- naive patients (Oral antidiabetic treatment or GLP-1 receptor agonist)	Insulin glargine (100 Units/mL)* ≥20 to <30 Units	Insulin glargine (100 Units/mL)* ≥30 to <60 Units
Starting Dose	SOLIQUA® (10-40) Pen	10 dose steps (10 Units/5 mcg)**	20 dose steps (20 Units/10 mcg)**	
	SOLIQUA® (30-60) Pen			30 dose steps (30 Units/10 mcg)**

\* If a different basal insulin was used:  
• For twice daily insulin or insulin glargine (300 Units/mL), the total daily dose previously used should be reduced by 20% to choose the SOLIQUA® starting dose.  
• For any other basal insulin, the same rule as for insulin glargine (100 Units/mL) should be applied.

\*\* Units insulin glargine (100 Units/mL)/mcg lixisenatide.

- The prescription must state the dose range and strength of the SOLIQUA® pre-filled pen and the number of dose steps to be administered.
- The maximum daily dose is 60 dose steps (corresponds to 60 Units insulin glargine and 20 mcg lixisenatide).

## PHARMACIST GUIDANCE

- Pharmacists are encouraged to check that patients and caretakers are able to read the strength of SOLIQUA®, the dose range of the pre-filled pen, and the dose pointer of the pre-filled pen before dispensing SOLIQUA®.
- Pharmacists should also check that patients have been trained on how to use the pen.
- Pharmacists should clarify with the prescriber any incomplete prescription.

The Sanofi logo, featuring the word "sanofi" in a lowercase, sans-serif font. The letter "s" is purple, and the letter "i" has a purple dot.

## IMPORTANT SAFETY INFORMATION

**SOLIQUA® is supplied in a pre-filled pen and must only be used with this device; healthcare professionals must never use a syringe to withdraw SOLIQUA® from a pre-filled pen or dosing errors and serious harm can result.**

Refer to the SOLIQUA® Singapore Package Insert for additional prescribing recommendations.

Reporting adverse events: Please report medication errors or any side effects suspected to be associated with the use of the SOLIQUA® pen to Sanofi, either by telephone 65 62263836 or by email [PV.SIN@sanofi.com](mailto:PV.SIN@sanofi.com).

This document has been approved by HSA as of 06-12-2022

Revision date: December 2022



**sanofi-aventis Singapore Pte. Ltd.**

38 Beach Road, #18-11 South Beach Tower, Singapore 189767

Tel: +65 6226 3836 Fax: +65 6535 5836